MEDTRN — Meditrina Cyprus Share Price
Last trade - 00:00- €4.50m
- €4.81m
- €14.95m
- 44
- 96
- 46
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.76 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 5.24 | ||
| Price to Sales | 0.32 | ||
| EV to EBITDA | 4.01 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.48% | ||
| Return on Equity | 10.63% | ||
| Operating Margin | 8.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | 10.08 | 10.56 | 14.95 | n/a | n/a | 21.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Meditrina Cyprus PLC is a Cyprus-based company primarily engaged in investment activities. The Company's main activity is investments shares of other companies engaged in the trade of pharmaceutical products. The Company's subsidiaries include Synapsis Trading Ltd (Cyprus), Meditrina Bulgaria Ltd (Bulgaria), Medora EPE (Greece), Meditrina EPE (Greece), Meditrina Pharmaceuticals SRL (formerly Solartium Group SRL) (Romania) and Solartium Pharma SRL (Moldova).
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- May 21st, 2020
- Public Since
- September 29th, 2021
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Cyprus Stock Exchange
- Shares in Issue
- 45,000,000
- Address
- Anexartisias 1 kai Athinon 79, LIMASSOL, 3040
- Web
- Phone
- Auditors
- L.Gnaftis & Co. Ltd
Upcoming Events for MEDTRN
Similar to MEDTRN
Pharmaceutical Centre SA
Cyprus Stock Exchange
FAQ
As of Today at 21:59 UTC, shares in Meditrina Cyprus are trading at . This share price information is delayed by 15 minutes.
Shares in Meditrina Cyprus last closed at and the price had moved by over the past 365 days. In terms of relative price strength the Meditrina Cyprus share price has underperformed the FTSE Global All Cap Index by -2.5% over the past year.
There is no consensus recommendation for this security.
Find out moreMeditrina Cyprus does not currently pay a dividend.
Meditrina Cyprus does not currently pay a dividend.
Meditrina Cyprus does not currently pay a dividend.
To buy shares in Meditrina Cyprus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of , shares in Meditrina Cyprus had a market capitalisation of €4.50m.
Here are the trading details for Meditrina Cyprus:
- Country of listing: Cyprus
- Exchange: CYS
- Ticker Symbol: MEDTRN
Based on an overall assessment of its quality, value and momentum Meditrina Cyprus is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Meditrina Cyprus. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -0.13%.
As of the last closing price of , shares in Meditrina Cyprus were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Meditrina Cyprus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Meditrina Cyprus' directors